# Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/nivolumab-for-advanced-non-small-cell-lung-cancer-patients-with-mild-idiopathic/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Daichi Fujimoto,Makiko Yomota,Akimasa Sekine,Mitsunori Morita,Takeshi Morimoto,Yukio Hosomi,Takashi Ogura,Hiromi Tomioka,Keisuke Tomii |
| Citations | 92 |
| DOI | 10.1016/j.lungcan.2019.06.001 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2949042479 |
| PMID | 31182249 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Daichi Fujimoto](https://scholariq.org/researchers/daichi-fujimoto/)

## Paper journal

- [Lung Cancer](https://scholariq.org/journals/lung-cancer/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis](https://scholariq.org/topics/interstitial-lung-diseases-and-idiopathic-pulmonary-fibrosis/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.